BioSenic S.A. (BIOSB.XC)
| Previous close | 2.5950 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | 0.0938 x N/A |
| Day's range | 0.0906 - 0.0906 |
| 52-week range | 0.0906 - 2.5950 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 598.731M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3300 |
| Earnings date | 05 Sept 2024 - 09 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces that it has signed a new subscription agreement for a maximum EUR 2.1 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15"). GTO 15 has committed to s
Globe NewswireThe Enterprise Court of Nivelles approves the BioSenic restructuring plan
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein w
- GlobeNewswire
BioSenic to host Annual General Meeting on July 12, 2024
PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual general meeting t
